| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2017 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 000 | 7 | NIH | 11/5/2019 | $0 |
| | 2020 | 2017 | OPTIMUM THERAPEUTICS, LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 001 | 7 | NIH | 8/11/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2015 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01CA158300 | Synergistic chemo-siRNA combination therapy | 000 | 5 | NIH | 12/11/2018 | $0 |
| | 2019 | 2014 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01GM100487 | Multiscale computational models for developing combination cancer therapy | 000 | 4 | NIH | 11/19/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $390,100 ) |
| | 2017 | 2017 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 002 | 7 | NIH | 7/18/2017 | $390,100 |
| | 2017 | 2015 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01CA158300 | Synergistic chemo-siRNA combination therapy | 000 | 5 | NIH | 8/16/2017 | $0 |
| | 2017 | 2014 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 001 | 4 | NIH | 5/11/2017 | $1 |
| | 2017 | 2014 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 000 | 4 | NIH | 5/8/2017 | -$1 |
| | 2017 | 2014 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R01GM100487 | Multiscale computational models for developing combination cancer therapy | 000 | 4 | NIH | 7/4/2017 | $0 |
| | 2017 | 2012 | OPTIMUM THERAPEUTICS LLC | 1815 ASTON AVE STE 107 | CARLSBAD | CA | 92008-7340 | SAN DIEGO | USA | R43TR000356 | Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer | 000 | 1 | NIH | 2/8/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $390,100 ) |
| | 2016 | 2016 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 000 | 6 | NIH | 6/24/2016 | $390,100 |
| | 2016 | 2014 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01GM100487 | Multiscale computational models for developing combination cancer therapy | 000 | 4 | NIH | 7/18/2016 | $0 |
| | 2016 | 2014 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01EB015253 | Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs | 000 | 4 | NIH | 9/14/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $750,879 ) |
| | 2015 | 2015 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 001 | 5 | NIH | 6/17/2015 | $378,396 |
| | 2015 | 2015 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01CA158300 | Synergistic chemo-siRNA combination therapy | 000 | 5 | NIH | 8/10/2015 | $372,483 |
| | 2015 | 2014 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 000 | 4 | NIH | 3/16/2015 | $0 |
| | 2015 | 2012 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43CA162448 | Intra-bladder MMC & suramin for nonmuscle-invading & locally advanced bladder ca | 000 | 2 | NIH | 2/27/2015 | $0 |
| | 2015 | 2012 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01CA077091 | Telomeres, telomerase and chemotherapy: Bench to bedside | 000 | 9 | NIH | 6/4/2015 | $0 |
| | 2015 | 2012 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43TR000356 | Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer | 000 | 1 | NIH | 9/19/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $1,001,475 ) |
| | 2014 | 2014 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 000 | 4 | NIH | 5/14/2014 | $1 |
| | 2014 | 2014 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01GM100487 | Multiscale computational models for developing combination cancer therapy | 000 | 4 | NIH | 7/7/2014 | $337,479 |
| | 2014 | 2014 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01CA158300 | Synergistic chemo-siRNA combination therapy | 000 | 4 | NIH | 7/9/2014 | $361,309 |
| | 2014 | 2014 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01EB015253 | Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs | 000 | 4 | NIH | 9/9/2014 | $302,686 |
| | 2014 | 2012 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43CA162448 | Intra-bladder MMC & suramin for nonmuscle-invading & locally advanced bladder ca | 000 | 2 | NIH | 3/17/2014 | $0 |
| | 2014 | 2012 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R01CA077091 | Telomeres, telomerase and chemotherapy: Bench to bedside | 000 | 9 | NIH | 4/23/2014 | $0 |
| | 2014 | 2012 | OPTIMUM THERAPEUTICS LLC | 9363 TOWNE CENTRE DRIVE | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43TR000356 | Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer | 000 | 1 | NIH | 9/17/2014 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $1,336,756 ) |
| | 2013 | 2013 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01CA158300 | Synergistic chemo-siRNA combination therapy | 000 | 3 | NIH | 7/17/2013 | $350,134 |
| | 2013 | 2013 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01EB015253 | Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs | 000 | 3 | NIH | 8/19/2013 | $294,261 |
| | 2013 | 2013 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01GM100487 | Multiscale computational models for developing combination cancer therapy | 000 | 3 | NIH | 7/1/2013 | $325,667 |
| | 2013 | 2013 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 000 | 3 | NIH | 3/15/2013 | $175,545 |
| | 2013 | 2013 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 001 | 3 | NIH | 6/19/2013 | $191,149 |
| | 2013 | 2009 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R44CA107743 | RAPID RELEASE PACLITAXEL NANOPARTICLES FOR BLADDER CANCER INTRAVESTICAL THERAPY | 000 | 4 | NIH | 5/1/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $2,231,135 ) (Continued on the next page) |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R43TR000356 | Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer | 000 | 1 | NIH | 9/8/2012 | $344,460 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01EB015253 | Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs | 001 | 2 | NIH | 8/29/2012 | -$297,956 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01EB015253 | Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs | 002 | 2 | NIH | 8/31/2012 | $297,956 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01CA158300 | Synergistic chemo-siRNA combination therapy | 000 | 2 | NIH | 7/19/2012 | $372,483 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R43CA162448 | Intra-bladder MMC & suramin for nonmuscle-invading & locally advanced bladder ca | 000 | 2 | NIH | 8/28/2012 | $105,157 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01CA163015 | Targeting multiple signaling steps to achieve synergy | 001 | 2 | NIH | 9/21/2012 | $390,100 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01EB015253 | Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs | 000 | 2 | NIH | 8/27/2012 | $297,956 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235-4215 | FRANKLIN | USA | R44CA103133 | APOPTOSIS INDUCING TO ENHANCE TUMOR TARGETING | 000 | 4 | NIH | 4/5/2012 | $50,000 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01CA077091 | Telomeres, telomerase and chemotherapy: Bench to bedside | 000 | 9 | NIH | 4/23/2012 | $333,500 |
| | 2012 | 2012 | OPTIMUM THERAPEUTICS LLC | 2287 PALMLEAF COURT | COLUMBUS | OH | 43235 | FRANKLIN | USA | R01GM100487 | Multiscale computational models for developing combination cancer therapy | 000 | 2 | NIH | 8/2/2012 | $337,479 |
|
